造血干细胞移植后EB病毒相关PTLD的诊疗进展

刘启发; 林韧

doi:10.13201/j.issn.1004-2806.2019.09.002

造血干细胞移植后EB病毒相关PTLD的诊疗进展

刘启发^,,
林韧

- 南方医科大学南方医院(广州, 510515)
基金项目:
国家自然科学基金(No:81770190)

国家重点研发计划(No:2017YFA105500、2017YFA105504)

广州市科技计划项目(No:201707010213)

详细信息

通讯作者: 刘启发,E-mail:liuqifa@fimmu.com

中图分类号: R457.7

收稿日期: 2019-07-28

Progress in the diagnosis and treatment of EB virus-related PTLD after hematopoietic stem cell transplantation

LIU Qifa^,,
LIN Ren

More Information

Corresponding author: LIU Qifa, E-mail: liuqifa@fimmu.com

Received Date: 28 July 2019

摘要

- 造血干细胞移植 /
- EB病毒 /
- 移植后淋巴细胞增殖性疾病
- hematopoietic stem cell transplantation /
- EB virus /
- post-transplant lymphoproliferative disease

HTML全文

参考文献(20)

[1]	Romero S,Montoro J,Guinot M,et al.Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation[J].Leuk Lymphoma,2019,60:142-150.
[2]	Styczynski J,Gil L,Tridello G,et al.Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults:a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation[J].Clin Infect Dis,2013,57:794-802.
[3]	Sanz J,Arango M,Senent L,et al.EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases[J].Bone Marrow Transplant,2014,49:397-402.
[4]	Brunstein CG,Weisdorf DJ,Defor T,et al.Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation[J].Blood,2006,108:2874-2880.
[5]	Nash RA,Dansey R,Storek J,et al.Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases[J].Biol Blood Marrow Transplant,2003,9:583-591.
[6]	Lin R,Wang Y,Huang F,et al.Two Dose Levels of Rabbit Antithymocyte Globulin as Graft-versus-host Disease Prophylaxis in Haploidentical Stem Cell Transplantation:A Multicenter Randomized Study[J].BMC Med,2019,17:156.
[7]	Xuan L,Jiang X,Sun J,et al.Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation[J].Transplantation,2013,96:560-566.
[8]	Kanakry JA,Kasamon YL,Bolanos-Meade J,et al.Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis[J].Biol Blood Marrow Transplant,2013,19:1514-1517.
[9]	Styczynski J,van der Velden W,Fox CP,et al.Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation:Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines[J].Haematologica,2016,101:803-811.
[10]	Swerdlow SH,Campo E,Pileri S A,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127:2375-2390.
[11]	Fox CP,Burns D,Parker AN,et al.EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation:clinical features,viral load correlates and prognostic factors in the rituximab era[J].Bone Marrow Transplant,2014,49:280-286.
[12]	Xuan L,Jiang X,Sun J,et al.Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation[J].Transplantation,2013,96:560-566.
[13]	Wu M,Huang F,Jiang X,et al.Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation[J].PLoS One,2013,8:e77805.
[14]	Liu QF,Ling YW,Fan ZP,et al.Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation[J].Transpl Infect Dis,2013,15:379-392.
[15]	Lin R,Liu Q.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation[J].J Hematol Oncol,2013,6:94.
[16]	Doubrovina E,Oflaz-Sozmen B,Prockop SE,et al.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+lymphomas after allogeneic hematopoietic cell transplantation[J].Blood,2012,119:2644-2656.
[17]	Styczynski J,Einsele H,Gil L,et al.Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients:a comprehensive review of reported cases[J].Transpl Infect Dis,2009,11:383-392.
[18]	Leen AM,Bollard CM,Mendizabal AM,et al.Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation[J].Blood,2013,121:5113-5123.
[19]	Wu M,Sun J,Zhang Y,et al.Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments:a prospective study[J].Bone Marrow Transplant,2016,51:456-458.
[20]	Czyzewski K,Styczynski J,Krenska A,et al.Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder[J].Leuk Lymphoma,2013,54:503-506.